Published in final edited form as:

Cancer Lett. 2019 January ; 440-441: 135–144. doi:10.1016/j.canlet.2018.10.009.

2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) Induces Peripheral Blood Abnormalities and Plasma Cell Neoplasms Resembling Multiple Myeloma in Mice

Lei Wang^{#a,b}, Munish Kumar^{#b,c}, Qipan Deng^b, Xu Wang^b, Ming Liu^{b,d}, Zhaojian Gong^{b,e}, Shanshan Zhang^{b,f}, Xiaodong Ma^{a,b}, Zijun Y. Xu-Monette^g, Min Xiao^g, Qing Yi^b, Ken H. Young^g, Kenneth S. Ramos^h, and Yong Li^{b,2}

^aInstitute for Brain Research and Rehabilitation, South China Normal University, Guangzhou, China

^bDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland OH; USA

^cRaman Fellow (UGC), Department of Biochemistry, University of Allahabad, Allahabad, India

^dState Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China

^eDepartment of Stomatology, the Second Xiangya Hospital, Central South University, Changsha, China

^fDepartment of Stomatology, Xiangya Hospital, Central South University, Changsha, China.

^gDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

^hDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, College of Medicine, University of Arizona, Tucson, AZ, USA

[#] These authors contributed equally to this work.

Abstract

Although epidemiologic studies have suggested a possible association between occupational exposures to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and the risk of development of multiple myeloma, definitive evidence in support of this association is lacking. In the present study, we employed the Vk*Mye mouse model of multiple myeloma to assess the impact of TCDD exposure on multiple myeloma pathogenesis. TCDD induced splenomegaly and multiple peripheral blood abnormalities, including anemia and high serum IgG levels. In addition, TCDD triggered bone

² Correspondence should be addressed to Dr. Yong Li, liy2@ccf.org.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflicts of interest

The authors declare that they have no financial or non-financial competing interest.

lytic lesions, as well as renal protein deposition, a phenomenon associated with human myeloma kidney disease. Even in wild-type C57BL/6 mice, TCDD increased serum IgG levels, induced anemia, and increased plasma cell presence in the spleen and bone marrow, hallmarks of benign monoclonal gammopathy. Lastly, TCDD induced AKT activation and the DNA damage response, key pathogenic events in myeloma pathogenesis, in animal spleen and/or bone marrow. These data indicate that TCDD accelerates monoclonal gammopathy development and promotes progression to multiple myeloma in genetically-predisposed mice. This work offers the first direct experimental evidence establishing TCDD as an environmental risk factor for monoclonal gammopathy of undetermined significance and multiple myeloma.

Keywords

TCDD; Multiple Myeloma; Vk*Mye; Mice

1. Introduction

Multiple myeloma is a plasma cell neoplasm and the second most common hematological malignancy in the United States. An estimated 30,770 new cases of multiple myeloma and 12,770 deaths caused by multiple myeloma has been predicted in the United States in 2018 [1]. Virtually all multiple myeloma cases are preceded by a precursor condition, monoclonal gammopathy of undetermined significance (MGUS), and the prevalence of MGUS increases with age, ranging from 1.7% among individuals 50–59 years of age to 5% in those older than 70 years [2]. The risk of progression from MGUS to multiple myeloma is estimated to be 1% per year [3, 4]. Despite significant medical advances in multiple myeloma drug development in the last 20 year, multiple myeloma is still considered incurable. Multiple myeloma is regarded as a disease with environmental causes, yet its etiology and what prompts progression remain largely unclear.

Dioxins are a group of chemically related compounds that are persistent organic pollutants. Among all dioxin compounds, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is a highly toxic environmental contaminant of particular concern for veterans of the Vietnam War who may have been exposed to TCDD during theater use of Agent Orange as an herbicide. While TCDD is not produced commercially, except as a pure compound for scientific and biomedical research, it is formed as a byproduct of herbicide synthesis or in burning processes from waste incineration, metals production, and fossil-fuel and wood combustion. Due to the omnipresence of TCDD, virtually everyone world-wide has some background exposure to this agent. The significance of these environmental exposures remains hotly debated.

TCDD is identified a known human carcinogen by the International Agency for Research on Cancer (IARC) of the World Health Organization[5]. In IARC's most recent review monograph, overall, the strongest evidence for TCDD carcinogenicity is for all cancers combined, rather than for any specific site [5]. In addition, the association of TCDD exposure with lung cancer, sarcoma, and non-Hodgkin lymphoma is stronger than that for other cancers, including multiple myeloma. As noted, TCDD has also been extensively

studied for health effects linked to its presence as a contaminant in the herbicide Agent Orange, which was sprayed widely during the Vietnam War [6]. A committee of the Health and Medicine Division of the National Academies of Sciences, Engineering, and Medicine released the most recent report on exposure of veterans to Agent Orange, which concluded that evidence is sufficient for an association between Agent Orange exposure in Vietnam veterans and sarcoma, Hodgkin lymphoma, and non-Hodgkin lymphoma, but evidence is limited/suggestive for multiple myeloma, prostate cancer, and lung cancer [7]. Studies of exposure during the 2001 World Trade Center disaster have reported an increased risk of multiple myeloma in early responders and recovery workers [8, 9], who were most likely exposed to substantial doses of carcinogens, including TCDD [9]. A recent publication reports a 2.4-fold increased risk for MGUS in Vietnam veterans than a cohort of control veterans and high serum TCDD levels associated with high M-protein levels in all veterans [10]. However, these studies are associative in nature and only provide indirect evidence. To the best of our knowledge, no direct experimental evidence exists to support TCDD as an environmental carcinogen for multiple myeloma, as rodents exposed to TCDD develop lung tumors, renal tumors, and non-Hodgkin lymphomas rather than multiple myeloma [11, 12]. Further, immunoglobulin levels in these exposed animals have never been followed to assess for benign monoclonal gammopathy (the mouse equivalent of human MGUS) [11, 12].

The *MYC* oncogene is activated in 67% of cases of multiple myeloma but not in MGUS, suggesting that *MYC* activation may be key in the transition to MM [13, 14]. Bergsagel and colleagues generated a conditional transgenic mouse model (Vk**Myc*) with sporadic, activation-induced deaminase-dependent *Myc* activation in germinal center B cells. These mice develop benign monoclonal gammopathy, which progresses to multiple myeloma after 70 weeks [14]. This model is regarded as the best available mouse model of multiple myeloma because it recapitulates many of the biological and clinical features of human disease, including progression from MGUS to MM, target organ damage, anemia, and the “M-spike” (elevated serum IgG) ²⁷ It should be noted that the Vk**Myc* mouse line is generated in a C57bl/6 genetic background and that 2-year-old wild-type (WT) C57bl/6 mice have a high incidence of benign monoclonal gammopathy, which rarely progress to multiple myeloma [15]. Thus, aging WT C57bl/6 and Vk**Myc* mice are genetically predisposed to monoclonal gammopathy and multiple myeloma and represent suitable models for studying MGUS and multiple myeloma. Given that no rodent models of multiple myeloma have been used in the past to study the impact of TCDD in myeloma pathogenesis, we hypothesized that exposure to TCDD in the Vk**Myc* model would reveal whether TCDD is a *bona fide* promoter of multiple myeloma progression. Our data provide compelling evidence that TCDD accelerates benign monoclonal gammopathy in WT mice and promotes multiple myeloma progression in Vk**Myc* mice, providing the first direct experimental animal evidence to support TCDD as an environmental causative factor for multiple myeloma.

2. Materials and methods

2.1. Mice

Vk*Myc mice in the C57Bl/6J genetic background were generated and obtained by Dr. Bergsagel and genotyping was performed using PCR as previously reported [14]. Vk*Myc and wild-type (WT) C57BL/6J mice were crossed to obtain littermates of WT and Vk*Myc mice. Sex-matched WT and Vk*Myc mice (8 weeks old) were assigned to a treatment or control group based on body weight. The dosing regimen employed is presented in Figure 1a. The treatment group was injected intraperitoneally with 2.5 µg TCDD /kg body weight (Sigma-Aldrich, St. Louis, MO) diluted 1:10 in corn oil once a week per mouse for 24 weeks, for a total calculated accumulated TCDD dose of 60 µg/kg body weight. Equal volumes of corn oil per body weight were injected into WT and Vk*Myc mice as vehicle control groups. Treated mice were then housed without any further treatment for an additional 24 weeks (Figure 1a). Every 6 weeks, blood from 5 arbitrarily selected mice from each group was drawn and the IgG levels measured. At the end of the 48 weeks, mice were euthanized by isoflurane overdose followed by cervical dislocation. All animal experimentation was carried out in accordance with NIH guidelines and under protocols approved by the Cleveland Clinic Institutional Animal Care and Use Committee.

2.2. Blood assays

A complete blood count (CBC) was determined using the Advia 120 Hematology System (Siemens Healthineers, Erlangen, Germany). To measure total serum IgG, blood was collected into Eppendorf tubes, allowed to coagulate at room temperature for 5 minutes, and centrifuged for 10 minutes at 850 g. Total IgG in serum was then determined by ELISA using the Easy- TiterMouse IgG Assay Kit and Mouse IgG Isotype Control (Thermo Fisher Scientific, Rockford, IL) according to the manufacturer's protocol. For serum protein electrophoresis, sera were diluted 1:2 in normal saline buffer and then analyzed on a QuickGel Chamber apparatus using Precasted QuickGels (Helena Laboratories, Beaumont, TX) according to the manufacturer's instructions.

2.3. Flow cytometric analysis

Spleens and bone marrow were harvested from mice and mashed first through a 70-µm and then a 40-µm nylon strainer (Sigma-Aldrich, St. Louis, MO) into RPMI medium to generate single-cell suspensions, which were then treated with ACK (Ammonium-Chloride-Potassium) lysis buffer (Lonza, Anaheim, CA) to remove red blood cells (RBCs). Cells (10×10^6) were suspended in 0.2 mL PBS and incubated with PE anti-mouse CD138 (syndecan-1) (BioLegend, San Diego, CA) and APC Rat Anti-Mouse CD45R/B220 (clone RA3-6B2) (BD Biosciences, San Diego, CA) on ice in the dark room for 15 min. Cells were then washed twice with PBS and resuspended in 0.5 mL PBS; flow cytometric analysis was performed on a MACSQuant Analyzer 10 (BD Biosciences). A total of 1×10^5 events were collected. FlowJo software (BD Biosciences) was used for data analysis.

2.4. Histology and Confocal Microscopy

For histological examinations, tissues were fixed in 10% neutral buffered formalin, embedded in paraffin, decalcified in 14% EDTA solution (for bone tissues only) and serially sectioned (5 μ m thick). Sections were stained with hematoxylin and eosin (H&E). For immunofluorescence analysis, tissue sections (8 μ m thick) were fixed in 4% paraformaldehyde, blocked, reacted with the primary antibodies overnight against CD138 (#142503, BioLegend, San Diego, CA) or Ki67 (#ab16667, Abcam, Cambridge, MA), washed, incubated with secondary fluorescent-conjugated antibodies (goat anti-rabbit IgG H&L - Alexa Fluor 488, #ab150077, Abcam) followed by cover slipping with mounting media containing DAPI nuclear stain. Confocal images were acquired using a Leica TCS-SP5 confocal microscope (Leica Microsystems; Buffalo Grove, IL). All histology analyses were performed using 3 sections from 5 animals in each group.

2.5. Western blot analyses

Splenocytes and bone marrow cells (10×10^6) were lysed with RIPA buffer (Thermo Fisher Scientific, Rockford, IL) containing protease and phosphatase inhibitor cocktails (Thermo Fisher Scientific, Rockford, IL); and protein concentration was measured with a BCA protein assay kit (Thermo Fisher Scientific, Rockford, IL). After mixing with Laemmli sample buffer (Bio-Rad Laboratories, Hercules, CA) containing 10% β -mercaptoethanol, the cell lysates were denatured at 95°C for 5 min. Equal amounts of proteins were loaded on 10% to 15% SDS-polyacrylamide gels (Mini-PROTEAN TGX Precast gels, Bio-Rad, Hercules, California); separated proteins were transferred onto PVDF membranes. The membrane was blocked using 5% nonfat dry milk in TBS-Tween-20 (0.1%, v/v) for 1 hour and incubated with primary antibody at 4°C overnight. The antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA): caspase-3 (#9662), PARP (#9542), p53 (#2524), p-p53 (#9286), PUMA (#7467), Akt (#2920), p-Akt (Ser473) (#4060) and β -actin (#3700). p21 (#6246) antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG was used as the secondary antibody. Immunoreactive protein was visualized with the Pierce Dura Western blotting substrate (Thermo Fisher Scientific, Rockford, IL). X-ray film images were quantified by scanning densitometry using area integration.

2.6. Statistics

Statistical analysis was carried out using GraphPad InStat 3 software (GraphPad Software, Inc., San Diego, CA, USA). The statistical significance between the groups was determined by one-way or two-way analysis of variance (ANOVA) with the appropriate *post hoc* testing using Tukey's Test. Significance was set at $P = 0.05$.

3. Results

3.1. TCDD induces splenomegaly in Vk*Myd mice

Vk*Myd mice and their WT littermates were given intraperitoneal injections of 2.5 μ g/kg TCDD or corn oil for 24 weeks. Animals were monitored at six-week intervals and maintained for an additional 24-week period before sacrifice (Figure 1a). Gross pathologic

analysis of animals at the 48-week necropsy revealed no major internal organ defects, except for a pronounced increase in spleen weights in Vk*Mye mice treated with TCDD compared to corn oil-treated counterparts or TCDD-treated WT mice (Figure 1b, c). TCDD significantly increased splenocyte numbers per organ in both WT and Vk*Mye mice, with the highest numbers found in Vk*Mye mice treated with TCDD (Figure 1d). Histopathologic analysis revealed that the spleens of vehicle- treated WT and Vk*Mye mouse had normal splenic organization, with clearly identifiable regions of red and white pulp (Figure 1e). These histological characteristics were preserved in spleens from WT mice receiving TCDD, but not in spleens of Vk*Mye mice receiving TCDD. Spleens from Vk*Mye mice challenged with TCDD exhibited marked histological disorganization, along with a reduction of lymphoid white pulp and expansion of hematogenous red pulp (Figure 1e). These findings indicate that TCDD treatment is associated with splenomegaly and this response appears to involve disruption of growth regulatory control in splenocytes. These actions of TCDD were magnified in mice genetically predisposed by activating mutation in the *Myc* gene.

3.2. TCDD-treated Vk*Mye mice develop multiple peripheral blood abnormalities

Serum IgG levels in Vk*Mye mice treated with TCDD did not increase during the 24-week treatment period. However, sharp increases were detected between weeks 24 and 48 after dosing in both WT and Vk*Mye mice treated with TCDD (Figure 2a). Compared to corn oil treated WT mice where stable IgG levels were measured at all times, TCDD-treated WT mice showed steady increases in IgG levels. In the case of Vk*Mye mice treated with TCDD, IgG levels reached 17.8 g/L compared to 3.8 g/L in vehicle-treated Vk*Mye mice at week 36. By 48 weeks, serum levels of total IgG in Vk*Mye mice treated TCDD increased to about 19.4 g/L, a net increase that represents a >5-fold of that (3.2 g/L) of vehicle-treated Vk*Mye mice ($p < 0.01$; Figure 2b). WT mice treated with TCDD also exhibited increased IgG levels compared to corn oil controls, albeit at considerably reduced levels compared to genetically-susceptible Vk*Mye mice. Serum protein electrophoresis (SPEP) analysis was performed for all mice: significant IgG monoclonal peaks, i.e., M-spike, were evident in Vk*Mye mice treated with TCDD, and to a lesser extent in TCDD-treated WT mice (Figure 2c). None of the vehicle-treated Vk*Mye mice or WT mice had an M-spike. This is the first direct evidence of blood abnormalities consistent with multiple myeloma in mice treated with TCDD, a response that is magnified in mice genetically predisposed to multiple myeloma.

The complete blood count showed multiple blood abnormalities in mice following TCDD treatment. TCDD decreased hemoglobin concentration in both WT and Vk*Mye mice compared to respective controls, but the decrease was markedly pronounced in Vk*Mye mice (Figure 2d). The red blood cell (RBC) and white blood cell (WBC) counts were also reduced by TCDD (Figure 2e, f), with significant increases in RBC mean cell volume (MCV) seen in Vk*Mye, but not WT mice (Figure 2g). The platelet counts and hematocrit (HCT) were also significantly reduced in TCDD-treated Vk*Mye mice (Figure 2h, i). Overall, TCDD induced blood dyscrasias such as anemia in both WT and Vk*Mye mice, with a stronger impact on Vk*Mye mice.

3.3. Progressive plasma cell neoplasms found in Vk*Myc mice treated with TCDD

High CD138 expression in the absence of B220 expression (CD138^{hi} B220⁻) is recognized as a prominent marker profile of plasma cells [16]. To determine if there was expansion of plasma cells, flow cytometry analyses of splenocytes and bone marrow cells were performed. An increase in the numbers of CD138^{hi} B220⁻ cells was detected in both WT and Vk*Myc mice treated with TCDD (Figure 3a). TCDD-treated WT and Vk*Myc mice harbored an average 2.1% and 4.7% CD138^{hi} B220⁻ plasma cells in spleens, respectively, a significant increase compared with vehicle-treated counterparts (Figure 3b). Similarly, the bone marrow of TCDD-treated WT and Vk*Myc mice contained approximately 1.5% and 5.8% CD138^{hi} B220⁻ plasma cells, whereas the bone marrow from the vehicle-treated control groups had less than 1% plasma cells (Figure 3c).

To determine plasma cell localization and compartmentalization in the spleen and bone marrow, we stained sections of spleen and bone marrow using antibodies against CD138⁺ (plasma cells) and Ki67⁺ (a marker for proliferation). CD138⁺ cells were predominantly located in the spleen and bone marrow of TCDD-treated Vk*Myc mice compared to WT TCDD-treated mice. A moderate increase in Ki67⁺ neoplastic plasma cell nuclei was also detected in the spleen (Figure 3d), but not in the bone marrow (Figure 3e). These data support that TCDD treatment increases the presences of proliferative plasma cells in the spleen but not in the bone marrow in Vk*Myc mice.

3.4. Target organ damage in mice treated with TCDD

To investigate the degree of target organ damage, bone, spleen, kidney, liver, and lung were sectioned and stained with hematoxylin and eosin (H&E). The bone structure was damaged in TCDD-treated Vk*Myc mice as evidenced by bone lytic lesions in the femoral shaft (Figure 4a). These lesions extended to the outside surface of the bone. We also observed minor bone lesions in TCDD-treated WT mice and vehicle-treated Vk*Myc mice, but not in vehicle-treated WT mice (Figure 4a). H&E staining also confirmed the presence of plasma cells in the bone marrow and spleen in TCDD-treated WT and Vk*Myc mice (Figure 4b). These plasma cells exhibited characteristic features --- royal blue cytoplasm, paranuclear clear zone, eccentric round nucleus, and clumped chromatin. Compared with the 3 other groups, more plasma cell nests were found in the bone marrow and spleen of Vk*Myc mice with TCDD treatment (Figure 4b, c).

Next, we analyzed the histopathologic changes in the kidney, liver, and lung in all groups of mice. Tubular casts, in the form of protein deposition, were found in the kidneys of both TCDD-treated groups, but not in the vehicle control groups; TCDD-treated WT kidneys had smaller and fewer casts than Vk*Myc mice (Figure 4d, upper panel). TCDD-treated Vk*Myc mice displayed hepatic fibrosis and collagen deposition, whereas TCDD-treated WT mice showed a less severe phenotypes; the 2 vehicle-treated groups showed normal lobular hepatic architectures (Figure 4d, middle panel). The lungs in TCDD-treated Vk*Myc mice were severely damaged, with destruction of lung alveoli, inflammatory cell infiltration, and thickening of the lung interstitium as compared to the WT counterpart; in contrast, the vehicle-treated WT and Vk*Myc mice showed no significant lung damage (Figure 4d, lower

panel). Taken together, these data indicate that TCDD treatment damages multiple organs in both WT and Vk*Myc mice with increased severity of damage in Vk*Myc mice.

3.5. AKT and DNA damage response are activated by TCDD

Because AKT plays a crucial role in intracellular signal transduction pathways that regulate cell growth, survival, transformation, and tumorigenesis [17, 18], we determined the status of AKT in mice with TCDD treatment. The activation of AKT in splenocytes was significantly increased in both TCDD-treated WT and Vk*Myc mice; and the response was most pronounced in Vk*Myc mice (Figure 5a). Likewise, AKT phosphorylation was strong in bone marrow cells from TCDD-treated WT and Vk*Myc mice (Figure 5b). These findings demonstrate that TCDD treatment induces activation of AKT in the bone marrow and spleen, particularly in Vk*Myc mice.

We determined splenocyte expression of caspase-3 and poly(ADP-ribose) polymerase (PARP). As a marker of apoptosis, cleaved caspase-3 was detected at low levels in mice without TCDD treatment. With TCDD treatment, cleaved caspase-3 was significantly increased in the spleen of both WT and Vk*Myc mice, with Vk*Myc mice having more cleaved caspase-3 than WT mice. Caspase-mediated PARP cleavage was enhanced by TCDD treatment in the spleen of both WT and Vk*Myc mice. We also assessed activation of the p53 signaling pathway (Figure 5b). The phosphorylation of p53 was induced in both the spleen and bone marrow of Vk*Myc mice by TCDD treatment. In the spleen of TCDD-treated mice, we also detected significant upregulation of two p53 targets, PUMA (p53-upregulated modulator of apoptosis) and p21 (a cell cycle regulator). We were unable to detect the expression of caspase 3, PARP, Puma, and p21 in the bone marrow in any group. These results demonstrate that TCDD activates Akt and the DNA damage response, particularly in Vk*Myc mice.

4. Discussion

Multiple myeloma is an incurable hematological neoplasm that causes over 10,000 deaths annually in the United States [1]. Multiple myeloma is regarded as an environmental disease, yet its etiology remains largely unclear. The association of multiple myeloma with smoking has been investigated, with some studies suggesting a strong association [19, 20], while others refuting this relationship [21–23]. An expert panel reviewing ~40 epidemiologic studies on TCDD, a contaminant hydrocarbon present in Agent Orange, and the risks of multiple myeloma found that there is an elevated risk of multiple myeloma in three fourths of all studies examined [24], but concluded that due to lack of experimental animal data, evidence is limited to support the association of multiple myeloma risk and TCDD exposure. The IARC classified TCDD as a Group 1 human carcinogen in 1997, but its carcinogenic implications in multiple myeloma were poorly understood, and multiple myeloma was only sporadically reported among workers exposed to TCDD [25]. Here, compelling evidence is presented establishing the Vk*Myc mouse line as a valid model to study the impact of TCDD exposure in multiple myeloma pathogenesis.

Multiple myeloma is a clonal B-cell disease of plasma cells that slowly proliferate and secrete IgG proteins. These neoplastic plasma cells grow in the bone marrow, causing bone

lesions [26]. Approximately 90% of patients with multiple myeloma develop bone disease, and 80% suffer from bone fractures [27–29]. Even patients with MGUS are at risk for increased bone porosity and reduced bone strength [30, 31]. Anemia is also a cardinal feature of multiple myeloma, present in most patients at diagnosis and during follow-up. In our work, following TCDD treatment, Vk*MyC mice have bone lytic lesions and high IgG levels similar to those encountered in patients with multiple myeloma. In addition, TCDD-treated mice demonstrate marked anemia with a decreased hemoglobin concentration and RBC numbers. Splenomegaly is characterized by a marked increase in organ cellularity, which usually rises from compromised extramedullary hematopoiesis, including anemia. Spleen size and weight were strikingly increased in TCDD-treated Vk*MyC mice, suggesting an immune proliferative disorder. CD138 is a transmembrane heparin sulfate proteoglycan normally expressed on plasma cells but not on B-cells. B220 (also known as CD45), a transmembrane protein tyrosine phosphatase, is commonly used as a B cell marker in mice and predominantly expressed on B lymphocytes, including pro-, mature, and activated B cells. Upon TCDD treatment, Vk*MYC mice accumulated terminally differentiated CD138⁺B220⁺ plasma cells in both the bone marrow and the spleen. Ki-67, as a proliferation-associated nuclear protein, is used to evaluate the proliferative activity of cancer [32, 33]. In the bone marrow, proliferating plasma cells is a feature of plasmacytoma, whereas quiescent plasma cells predominate in multiple myeloma [14]. Following TCDD treatment, plenty of cells in the spleen, and a minority of cells in the bone marrow of Vk*MyC mice, co-stained with CD138 and Ki67. TCDD-treated WT mice also exhibited elevated serum IgG levels, reduced hemoglobin and RBC numbers, and increased plasma cells in the bone marrow and spleen, but these changes were mild compared to those in TCDD-treated Vk*MyC mice. Our results indicate that TCDD accelerates MGUS and promotes progression to multiple myeloma in genetically predisposed mice. Given that TCDD is not a mutagen, the degree to which this agent acts to drive oncogenic events and interacts with other environmental triggers of genetic damage to induce MGUS and multiple myeloma in mice or humans remains to be defined.

Renal impairment is an important clinical hallmark of multiple myeloma, being present in up to 50% of patients newly diagnosed with multiple myeloma [34–37]. WT mice treated with TCDD exhibit protein deposition in the kidney, and this deposition is more severe in TCDD-treated Vk*MyC mice. Previous reports demonstrate that mice with TCDD treatment develop hepatic fibrosis [38–41] and inflammatory pulmonary lesions [42, 43], which we also observed in both WT and Vk*MyC mice exposed to TCDD. Several studies have reported lung involvement in human multiple myeloma, including fibrosis, mass lesions, multiple nodular lesions and interstitial infiltrates [44–47]. TCDD is regarded as one of the most potent hepatic carcinogens in rodent models [48]. The observed liver and lung pathology in TCDD-treated mice is likely a direct response to TCDD, rather than a secondary complication of high serum IgG levels. However, renal protein deposition has not been reported in TCDD-treated rodents previously [11]. Thus, protein deposition in the kidney of TCDD-treated Vk*MyC mice is likely a result of the high serum IgG levels, i.e., a complication caused by multiple myeloma progression.

Genes in the RAS signaling pathway, like KRAS and NRAS, are frequently mutated in multiple myeloma [49], and AKT is a major effector pathway of RAS activation.

Constitutive activation of AKT is reported to be an oncogenic signal in multiple myeloma and is associated with poor patient prognosis [50]. In this study, we showed that AKT is activated in splenocytes and bone marrow cells in both WT and Vk*Myb mice exposed to TCDD. Cleavage of PARP is a marker for DNA damage and apoptosis [51, 52]. We observed that cleaved caspase-3 and cleaved PARP were upregulated in mice with TCDD exposure. As a transcriptional regulator, p53 is activated (phosphorylated) in response to DNA damage, oncogene activation and other stresses, resulting transactivation of p21 and Puma [53, 54]. Constitutive ongoing DNA damage is found in human multiple myeloma [55]. In our work, the levels of p53 phosphorylation and p21 and Puma expression in splenocytes and p53 in bone marrow cells were significantly higher in the TCDD-treated mice than in the vehicle-treated control groups, providing evidence suggesting that TCDD exposure induces the DNA damage response. We observed AKT activation and an enhanced DNA damage response at 24 weeks after the completion of TCDD treatment, suggesting the effect of TCDD is indirect or of epigenetic nature.

To summarize, our data provide *in vivo* evidence to support that TCDD accelerates MGUS and promotes disease progression to multiple myeloma and uncover the relevant molecular mechanisms of progression. Previously, definitive evidence is limited to support the association of Agent Orange (i.e., TCDD) exposure in Vietnam veterans and multiple myeloma [7]. Our data, in combination with the epidemiologic study connecting high serum TCDD levels to increased MGUS incidence [10], provides experimental evidence to support that TCDD is an underlying cause for increased prevalence of multiple myeloma and MGUS. Identifying TCDD as a contributing etiologic factor in multiple myeloma and its precursor MGUS opens new doors for cancer prevention for the more than 1 million MGUS patients at risk for the incurable multiple myeloma. Because of government regulations, voluntary changes in industrial practices, and improvements in manufacturing, industrial processes are no longer major sources of TCDD in the United States. Yet TCDD has a long enduring half-life in the environment and it is still emitted in uncontrolled waste incinerators and other sources due to incomplete burning. The present study further underscores the relationship between multiple myeloma and TCDD exposure, particularly for those who have MGUS.

Acknowledgements

LW, MK, KSR, and YL designed the research. All authors performed experiments and/or contributed to data analyses. LW, KSR, and YL wrote the manuscript, and all authors provided critical review and revisions and approved the final version of the manuscript. The authors are grateful to Dr. Cassandra Talerico for editing the manuscript and providing critical comments. This study was supported by NIH R01 grants (CA138688 and CA177810 to YL), National Natural Science Foundation of China (NO. 31500326 to LW), and Natural Science Foundation of Guangdong Province of China (NO. 2017A030313194 to LW).

References

- [1]. Siegel RL, Miller KD, Jemal A, Cancer statistics, 2018, CA: a cancer journal for clinicians, 68 (2018) 7–30.
- [2]. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ, Prevalence of monoclonal gammopathy of undetermined significance, New Engl J Med, 354 (2006) 1362–1369. [PubMed: 16571879]

- [3]. Turesson I, Kovalchik SA, Pfeiffer RM, Kristinsson SY, Goldin LR, Drayson MT, Landgren O, Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden, *Blood*, 123 (2014) 338–345. [PubMed: 24222331]
- [4]. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton L, A long-term study of prognosis in monoclonal gammopathy of undetermined significance, *New Engl J Med*, 346 (2002) 564–569. [PubMed: 11856795]
- [5]. Baan R, Grosse Y, Straif K, Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Coglian V, Wo WIARCM, Special Report: Policy A review of human carcinogens-Part F: Chemical agents and related occupations, *Lancet Oncol*, 10 (2009) 1143–1144. [PubMed: 19998521]
- [6]. Pavuk M, Michalek JE, Schecter A, Ketchum NS, Akhtar FZ, Fox KA, Did TCDD exposure or service in southeast Asia increase the risk of cancer in air force Vietnam veterans who did not spray agent orange?, *J Occup Environ Med*, 47 (2005) 335–342. [PubMed: 15824624]
- [7]. Acquavella J, Garabrant D, Marsh G, Sorahan T, Weed DL, Glyphosate epidemiology expert panel review: a weight of evidence systematic review of the relationship between glyphosate exposure and non-Hodgkin's lymphoma or multiple myeloma, *Crit Rev Toxicol*, 46 (2016) 28–43. [PubMed: 27677668]
- [8]. Moline JM, Herbert R, Crowley L, Troy K, Hodgman E, Shukla G, Udasin I, Luft B, Wallenstein S, Landrigan P, Savitz DA, Multiple Myeloma in World Trade Center Responders: A Case Series, *Journal of occupational and environmental medicine*, 51 (2009) 896–902 810.1097/JOM.1090b1013e3181ad1049c1098. [PubMed: 19620891]
- [9]. Li J, Cone JE, Kahn AR, et al., Association between world trade center exposure and excess cancer risk, *Jama*, 308 (2012) 2479–2488. [PubMed: 23288447]
- [10]. Landgren O, Shim YK, Michalek J, et al., Agent orange exposure and monoclonal gammopathy of undetermined significance: An operation ranch hand veteran cohort study, *JAMA Oncology*, 1 (2015) 1061–1068. [PubMed: 26335650]
- [11]. The WHO International Agency for Research on Cancer Monograph Working Group, 2,3,7,8-TCDD, 2,3,4,7,8-PeCDF, and PCB 126, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, The WHO Press 2012, pp. 339–378.
- [12]. Baan R, Grosse Y, Straif K, Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Coglian V, A review of human carcinogens-- Part F: chemical agents and related occupations, *The Lancet. Oncology*, 10 (2009) 1143–1144. [PubMed: 19998521]
- [13]. Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T, Mulligan G, Chesi M, Bergsagel PL, Fonseca R, Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma, *Leukemia*, 25 (2011) 1026–1035. [PubMed: 21468039]
- [14]. Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R, Valdez R, Palmer SE, Haas SS, Stewart AK, Fonseca R, Kremer R, Cattoretti G, Bergsagel PL, AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies, *Cancer Cell*, 13 (2008) 167–180. [PubMed: 18242516]
- [15]. van den Akker TW, de E Veer Glopper-van der, Radl J, Benner R, The influence of genetic factors associated with the immunoglobulin heavy chain locus on the development of benign monoclonal gammopathy in ageing IgH-congenic mice, *Immunology*, 65 (1988) 31–35. [PubMed: 3141270]
- [16]. Sanderson RD, Borset M, Syndecan-1 in B lymphoid malignancies, *Ann Hematol*, 81 (2002) 125–135. [PubMed: 11904737]
- [17]. Manning BD, Toker A, AKT/PKB Signaling: Navigating the Network, *Cell*, 169 (2017) 381–405. [PubMed: 28431241]
- [18]. Sever R, Brugge JS, Signal Transduction in Cancer, *Csh Perspect Med*, 5 (2015).
- [19]. Williams RR, Horn JW, Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: interview study from the Third National Cancer Survey, *Journal of the National Cancer Institute*, 58 (1977) 525–547. [PubMed: 557114]

- [20]. Mills PK, Newell GR, Beeson WL, Fraser GE, Phillips RL, History of Cigarette Smoking and Risk of Leukemia and Myeloma: Results From the Adventist Health Study, *Journal of the National Cancer Institute*, 82 (1990) 1832–1836. [PubMed: 2250299]
- [21]. Fernberg P, Odenbro A, Belloc R, Boffetta P, Pawitan Y, Zendehdel K, Adami J, Tobacco use, body mass index, and the risk of leukemia and multiple myeloma: a nationwide cohort study in Sweden, *Cancer Res*, 67 (2007) 5983–5986. [PubMed: 17575169]
- [22]. Psaltopoulou T, Sergentanis TN, Kanellias N, Kanavidis P, Terpos E, Dimopoulos MA, Tobacco smoking and risk of multiple myeloma: A meta-analysis of 40 observational studies, *International journal of cancer*, (2012) n/a-n/a.
- [23]. Castillo JJ, Dharni PK, Curry S, Brennan K, No association between cigarette smoking and incidence of plasma cell myeloma: A meta-analysis of 17 observational studies, *American Journal of Hematology*, 87 (2012) 729–731. [PubMed: 22566293]
- [24]. C.I.R.t.H.E.i.V.V.o.E.t. Herbicides, Veterans and Agent Orange: Update 1998, National Academy Press, Washington, D.C., 1999.
- [25]. Baan R, Grosse Y, Straif K, Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Coglian V, A review of human carcinogens—Part F: Chemical agents and related occupations, *The Lancet Oncology*, 10 1143–1144.
- [26]. Slovak ML, Multiple Myeloma: Current Perspectives, *Clin Lab Med*, 31 (2011) 699–+. [PubMed: 22118745]
- [27]. Melton LJ, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV, Fracture risk with multiple myeloma: A population-based study, *J Bone Miner Res*, 20 (2005) 487–493. [PubMed: 15746994]
- [28]. Pappa CA, Tsirakis G, Psarakis FE, Kolovou A, Tsigaridaki M, Stafylaki D, Sfiridaki K, Alexandrakis MG, Lack of correlation between angiogenic cytokines and serum insulin-like growth factor-1 in patients with multiple myeloma, *Med Oncol*, 30 (2013).
- [29]. Kristinsson SY, Minter AR, Korde N, Tan E, Landgren O, Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management, *Expert Rev Mol Diagn*, 11 (2011) 593–603. [PubMed: 21745013]
- [30]. Farr JN, Zhang W, Kumar SK, Jacques RM, Ng AC, McCready LK, Rajkumar SV, Drake MT, Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance, *Blood*, 123 (2014) 647–649. [PubMed: 24227822]
- [31]. Ng AC, Khosla S, Charatcharoenwithaya N, Kumar SK, Achenbach SJ, Holets MF, McCready LK, Melton LJ, Kyle RA, Rajkumar SV, Drake MT, Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1 alpha levels in patients with MGUS, *Blood*, 118 (2011) 6529–6534. [PubMed: 22042700]
- [32]. Dziegiel P, Salwa-Zurawska W, Zurawski J, Wojnar A, Zabel M, Prognostic significance of augmented metallothionein (MT) expression correlated with Ki-67 antigen expression in selected soft tissue sarcomas, *Histol Histopathol*, 20 (2005) 83–89. [PubMed: 15578426]
- [33]. Urruticoechea A, Smith IE, Dowsett M, Proliferation marker Ki-67 in early breast cancer, *J Clin Oncol*, 23 (2005) 7212–7220. [PubMed: 16192605]
- [34]. Alexanian R, Barlogie B, Dixon D, Renal-Failure in Multiple-Myeloma – Pathogenesis and Prognostic Implications, *Arch Intern Med*, 150 (1990) 1693–1695. [PubMed: 2383164]
- [35]. Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H, Pathogenesis and treatment of renal failure in multiple myeloma, *Leukemia*, 22 (2008) 1485–1493. [PubMed: 18528426]
- [36]. Soleymanian T, Soleimani A, Musavi A, Mojtahedi K, Hamid G, Outcome of patients with multiple myeloma and renal failure on novel regimens, *Saudi J Kidney Dis T*, 27 (2016) 335–340.
- [37]. Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, Michali E, Economopoulos T, Zervas K, Dimopoulos MA, Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance, *Leukemia Lymphoma*, 48 (2007) 337–341. [PubMed: 17325894]
- [38]. Han M, Liu X, Liu S, Su G, Fan X, Chen J, Yuan Q, Xu G, 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces hepatic stellate cell (HSC) activation and liver fibrosis in C57BL/6 mouse via

activating Akt and NF-kappaB signaling pathways, *Toxicol Lett*, 273 (2017) 10–19. [PubMed: 28302560]

- [39]. Pierre S, Chevallier A, Teixeira-Clerc F, Ambolet-Camoit A, Bui L-C, Bats A-S, Fournet J-C, Fernandez-Salguero P, Aggerbeck M, Lotersztajn S, Barouki R, Coumoul X, Aryl Hydrocarbon Receptor-Dependent Induction of Liver Fibrosis by Dioxin, *Toxicological Sciences*, 137 (2014) 114–124. [PubMed: 24154488]
- [40]. Kopec AK, Boverhof DR, Nault R, Harkema JR, Tashiro C, Potter D, Sharratt B, Chittim B, Zacharewski TR, Toxicogenomic Evaluation of Long-term Hepatic Effects of TCDD in Immature, Ovariectomized C57BL/6 Mice, *Toxicological Sciences*, 135 (2013) 465–475. [PubMed: 23864506]
- [41]. Nault R, Fader KA, Ammendolia DA, Dornbos P, Potter D, Sharratt B, Kumagai K, Harkema JR, Lunt SY, Matthews J, Zacharewski T, Dose-Dependent Metabolic Reprogramming and Differential Gene Expression in TCDD-Elicited Hepatic Fibrosis, *Toxicological Sciences*, 154 (2016) 253–266. [PubMed: 27562557]
- [42]. Ishimaru N, Takagi A, Kohashi M, Yamada A, Arakaki R, Kanno J, Hayashi Y, Neonatal Exposure to Low-Dose 2,3,7,8-Tetrachlorodibenzo-p-Dioxin Causes Autoimmunity Due to the Disruption of T Cell Tolerance, *The Journal of Immunology*, 182 (2009) 6576–6586. [PubMed: 19414813]
- [43]. Wong PS, Vogel CF, Kokosinski K, Matsumura F, Arylhydrocarbon Receptor Activation in NCI-H441 Cells and C57BL/6 Mice Possible Mechanisms for Lung Dysfunction, *Am J Resp Cell Mol*, 42 (2010) 210–217.
- [44]. Kamble R, Rosenzweig T, Diffuse pulmonary parenchymal involvement in multiple myeloma: Antemortem diagnosis, *Int J Hematol*, 83 (2006) 259–261. [PubMed: 16720559]
- [45]. Yuan Y, Wiecezorek R, Green DL, Cook P, Ballard H, Araten DJ, Multiple Myeloma Involving Skin and Pulmonary Parenchyma after Autologous Stem Cell Transplantation, *J Hematol Oncol*, 2 (2009).
- [46]. Yokote T, Akioka T, Miyamoto H, Oka S, Hara S, Yamano T, Takasu T, Tsuji M, Hanafusa T, Pulmonary parenchymal infiltrates in a patient with CD20-positive multiple myeloma, *Eur J Haematol*, 74 (2005) 61–65. [PubMed: 15613108]
- [47]. Chim CS, Wong M, Fan YS, Pulmonary interstitial amyloidosis complicating multiple myeloma, *J Clin Oncol*, 26 (2008) 504–506. [PubMed: 18202427]
- [48]. Knerr S, Schrenk D, Carcinogenicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in experimental models, *Mol Nutr Food Res*, 50 (2006) 897–907. [PubMed: 16977593]
- [49]. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, Keats JJ, Schumacher SE, Rosenberg M, Getz G, Golub TR, Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy, *Cancer Cell*, 25 (2014) 91–101. [PubMed: 24434212]
- [50]. Tu YP, Gardner A, Lichtenstein A, The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: Roles in cytokine-dependent survival and proliferative responses, *Cancer Res*, 60 (2000) 6763–6770. [PubMed: 11118064]
- [51]. Wang ML, Wu WZ, Wu WQ, Rosidi B, Zhang LH, Wang HC, Iliakis G, PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways, *Nucleic Acids Res*, 34 (2006) 6170–6182. [PubMed: 17088286]
- [52]. Aguenouz M, Vita GL, Messina S, Cama A, Lanzano N, Ciranni A, Rodolico C, Di Giorgio RM, Vita G, Telomere shortening is associated to TRF1 and PARP1 overexpression in Duchenne muscular dystrophy, *Neurobiol Aging*, 32 (2011) 2190–2197. [PubMed: 20137830]
- [53]. Robertson JD, Orrenius S, Molecular mechanisms of apoptosis induced by cytotoxic chemicals, *Crit Rev Toxicol*, 30 (2000) 609–627. [PubMed: 11055838]
- [54]. Green DR, Kroemer G, Cytoplasmic functions of the tumour suppressor p53, *Nature*, 458 (2009) 1127–1130. [PubMed: 19407794]
- [55]. Cottini F, Hideshima T, Suzuki R, Tai YT, Bianchini G, Richardson PG, Anderson KC, Tonon G, Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma, *Cancer Discov*, 5 (2015) 972–987. [PubMed: 26080835]

Highlights

- TCDD accelerated benign monoclonal gammopathy and multiple myeloma in genetically predisposed Vk*Myc mice.
- TCDD increased serum IgG levels, induced anemia, and increased plasma cell presence in the spleen and bone marrow in wild-type C57BL/6 mice, hallmarks of benign monoclonal gammopathy.
- TCDD triggered key pathogenic events in multiple myeloma progression.

Figure 1. TCDD treatment promotes splenomegaly in Vk*MyC mice.

(a) Schematic diagram of the experimental exposure regimen used in all 4 groups. (b) Mouse spleen weight at 48 weeks. (c) Representative images of spleens from 4 groups of mice (2 from each group). (d) The total number of splenocytes per spleen from mice at sacrifice. (e) Representative H&E-stained spleen sections from TCDD-treated Vk*MyC mice showing altered architecture with a reduction of lymphoid white pulp (WP) and an expansion of hematogenous red pulp (RP). Scale bar=200 μ m (top) or 25 μ m (bottom). Data in (b and d)

were analyzed by one-way ANOVA. The horizontal lines were presented as the mean value. n=5 mice per group. *, P 0.05; **, P 0.01; ***, P 0.001.

Figure 2. TCDD-treated Vk*MyC mice develop multiple peripheral blood abnormalities.

(a) Total serum IgG levels in mice during 24 weeks of TCDD treatment and the ensuing 24 weeks without treatment. Mice blood samples were collected and assayed for IgG concentration every 6 weeks. (b) Total serum IgG levels in mice at Week 48. (c) Immunoglobulins from mice as determined by SPEP at Week 48. Arrows indicate IgG monoclonal peaks (M-spikes; γ -globulin peak). SPEP was performed for all mice in each group and representative results of 2 mice per group were shown. (d-i) Complete blood cell counts in mice. Measured blood parameters included (d) hemoglobin (HGB) concentration, (e) red blood cell count (RBC), (f) white blood cell count (WBC), (g) mean red cell volume (MCV), (h) platelets, and (i) hematocrit (HCT). The horizontal lines show the mean values. Data were analyzed by two-way ANOVA (a) or one-way ANOVA (b, d-i). $n=5$ mice per group. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$.

Figure 3. Progressive plasma cell neoplasms in Vk*Mye mice treated with TCDD.

(a) Representative flow cytometry plots detecting cell surface markers CD138 (Y-axis) and B220 (X-axis) in splenocytes (upper panel) and bone marrow cells (lower panel). The numbers on the axes denote the $\log_{10}$ values of fluorescence (those of 3 on the right are the same as the ones on the left). The number in the inserts shows the percentage of CD138^{high}B220⁻ cells in the entire cell population. (b, c) Bar graphs of the percentages of CD138⁺B220⁻ and B220⁺ cells from spleen (b) and bone marrow (c). Data were analyzed by one-way ANOVA. *, $P = 0.05$; **, $P = 0.01$; ***, $P = 0.001$. (d) Confocal microscopy

images identifying Ki67⁺ (green) and CD138⁺ (red) expression with nuclear DAPI staining of cells in the spleen of WT (upper panel) and Vk*Myc mice (lower panel) treated with TCDD. Scale bar = 10 μ m. (e) Confocal microscopy images identifying Ki67⁺ (green) and CD138⁺ (red) expression with nuclear DAPI staining of cells in the bone marrow of WT (upper panel) and Vk*Myc mice (lower panel) treated with TCDD. Scale bar = 10 μ m. n=5 mice per group.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 4. Target organ damage in TCDD-treated mice.

(a) Histological evaluation of bone morphology in 4 groups of mice. Bone lytic lesions (indicated by arrows) were detected in the femoral shaft of Vk*MYC mice treated with TCDD. Scale bar = 200 μ m (top) or 50 μ m (bottom). (b) Infiltrating plasma cells in the bone marrow of TCDD-treated mice. Scale bar = 10 μ m. Arrows point to plasma cells. (c) Infiltrating plasma cells in the spleen of TCDD-treated mice. Scale bar = 10 μ m. Arrows point to plasma cells. (d) Damage to kidney, liver, and lung. Arrows point to protein deposition in kidney (upper panel, scale bar = 100 μ m), collagen deposition in liver (middle

panel, scale bar = 50 μm), and destruction of lung morphology (lower panel, scale bar = 50 μm) were observed in TCDD-treated Vk*Myc mice. n=5 mice per group.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 5. Splenocytes and bone marrow cells from TCDD-treated mice display AKT activation and markers of the DNA damage response.

(a) Western blot analyses of splenocytes from 4 groups of mice. (b) Western blot analyses of bone marrow cells from 4 groups of mice. β -actin was used as a control. $n = 5$ mice for each group with representative images from 1 animal in each group shown.